Evaluation of Memantine in the Preservation of Memory and Neurocognition Following CSI

Recruiting now · Phase 3

Conditions studied: Neurocognitive Dysfunction

In brief

The goal of this clinical trial is to evaluate the role of memantine in preservation of memory and neurocognition in patients undergoing craniospinal irradiation. Participants will be randomised into two arms and the interventional arm will receive memantine along with the standard treatment. Researchers will compare the neurocognitive tests of participants in both the arms to see if memantine leads to significant preservation of memory and cognition post radiation therapy.

Key facts

Study ID

NCT06275035

Run by

Tata Memorial Centre

People needed

101

Starts

2024-02-22

Expected to finish

2031-01-01

Last updated by the study team

2025-04-09

Who can join

Age: 5 and older, up to 39. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age at irradiation: 5 to 39 years
• Planned for CSI (with or without boost dose) with or without systemic chemotherapy
• Informed consent or assent taken
• Karnofsky Performance Status / Lansky Performance Status ≥ 60

You may not qualify if…

• Re-irradiation
• Prior exposure to memantine
• Inability to undergo Wechsler test

Where it is running

• Tata Memorial Hospital — Mumbai, Maharashtra, India (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.